Incidence and risk factors for developing chemotherapy‐induced neuropathic pain in 500 cancer patients: A file‐based observational study
Objective To define the incidence and risk factors for developing chemotherapy‐induced neuropathic pain (CINP). Methods Retrospective, file‐based analysis on cancer patients who received any type of conventional chemotherapy and for whom neurological evaluation was asked to reveal the extent of chem...
Gespeichert in:
| Veröffentlicht in: | Journal of the peripheral nervous system 2024-03, Vol.29 (1), p.38-46 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 46 |
|---|---|
| container_issue | 1 |
| container_start_page | 38 |
| container_title | Journal of the peripheral nervous system |
| container_volume | 29 |
| creator | Argyriou, Andreas A. Bruna, Jordi Kalofonou, Foteini Velasco, Roser Litsardopoulos, Pantelis Alemany, Montse Anastopoulou, Garifallia G. Kalofonos, Haralabos P. |
| description | Objective
To define the incidence and risk factors for developing chemotherapy‐induced neuropathic pain (CINP).
Methods
Retrospective, file‐based analysis on cancer patients who received any type of conventional chemotherapy and for whom neurological evaluation was asked to reveal the extent of chemotherapy‐induced peripheral neurotoxicity (CIPN) with or without CINP. CINP was assessed by means of the PI‐NRS and Douleur Neuropathique‐4 questionnaire. The total neuropathy score‐clinical version graded the severity of CIPN.
Results
The medical files of 500 chemotherapy‐treated cancer patients were reviewed. Any grade chronic CIPN was disclosed in 343 (68.6%) patients and CINP in 127 (37%) of them, corresponding to an overall percentage of 25.4% among all 500 included patients. The logistic regression analysis identified as independent predictors for CINP development the presence of uncomplicated diabetes (OR: 2.17; p = .039) and grade 2–3 chronic CIPN (OR: 1.61; p |
| doi_str_mv | 10.1111/jns.12616 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2925003294</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2937127268</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3536-3c4f2045fb3e0a5e8d9a2bfaba9ee29a662fdf4a67c981af7042cdd7ed4ba6d73</originalsourceid><addsrcrecordid>eNp1kc9uFSEUh4mxsbW68AUMiZu6mJY_M8Pgrmm01jS6UNeTM3Dwcp0LI8zU3J0P4KLP2Ccp9bYuTCQknMB3vgA_Ql5wdszLOFmHfMxFy9tH5IA3QlcdE-pxqVnXVLru9D55mvOaMa4010_Ivuwk51KqA_L7IhhvMRikECxNPn-nDswcU6YuJmrxCsc4-fCNmhVu4rzCBNP25te1D3YxaGnAJcUJ5pU3dAIfaJkNY9RAkaayNXsMc35DT6nzI5bOAXLpi0PGdFVOY4CR5nmx22dkz8GY8fn9eki-vnv75ex9dfnp_OLs9LIyspFtJU3tBKsbN0hk0GBnNYjBwQAaUWhoW-Gsq6FVRnccnGK1MNYqtPUArVXykBztvFOKPxbMc7_x2eA4QsC45F5oUV4gha4L-uofdB2XVG58R0nFhRJtV6jXO8qkmHNC10_JbyBte876u4j6ElH_J6LCvrw3LsMG7V_yIZMCnOyAn-W7tv839R8-ft4pbwGyOJ91</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2937127268</pqid></control><display><type>article</type><title>Incidence and risk factors for developing chemotherapy‐induced neuropathic pain in 500 cancer patients: A file‐based observational study</title><source>Access via Wiley Online Library</source><creator>Argyriou, Andreas A. ; Bruna, Jordi ; Kalofonou, Foteini ; Velasco, Roser ; Litsardopoulos, Pantelis ; Alemany, Montse ; Anastopoulou, Garifallia G. ; Kalofonos, Haralabos P.</creator><creatorcontrib>Argyriou, Andreas A. ; Bruna, Jordi ; Kalofonou, Foteini ; Velasco, Roser ; Litsardopoulos, Pantelis ; Alemany, Montse ; Anastopoulou, Garifallia G. ; Kalofonos, Haralabos P.</creatorcontrib><description>Objective
To define the incidence and risk factors for developing chemotherapy‐induced neuropathic pain (CINP).
Methods
Retrospective, file‐based analysis on cancer patients who received any type of conventional chemotherapy and for whom neurological evaluation was asked to reveal the extent of chemotherapy‐induced peripheral neurotoxicity (CIPN) with or without CINP. CINP was assessed by means of the PI‐NRS and Douleur Neuropathique‐4 questionnaire. The total neuropathy score‐clinical version graded the severity of CIPN.
Results
The medical files of 500 chemotherapy‐treated cancer patients were reviewed. Any grade chronic CIPN was disclosed in 343 (68.6%) patients and CINP in 127 (37%) of them, corresponding to an overall percentage of 25.4% among all 500 included patients. The logistic regression analysis identified as independent predictors for CINP development the presence of uncomplicated diabetes (OR: 2.17; p = .039) and grade 2–3 chronic CIPN (OR: 1.61; p < .001) as also the administration of combined paclitaxel plus cisplatin (reference variable), compared to oxaliplatin (OR: 0.18; p = .001) and taxanes (OR: 0.16; p < .001). The increased severity of acute OXAIPN was associated with CINP (OR: 4.51; p < .001). OXA‐treated patients with persistent CINP presented a worst likelihood to improve after chemotherapy discontinuation, than patients receiving combined paclitaxel plus cisplatin (OR: 50; p < .001).
Conclusion
The incidence of CINP in our cohort was comparable to previous reports, with severities fluctuating upwards during chemotherapy and declined post‐chemotherapy. Uncomplicated diabetes, the combined paclitaxel plus cisplatin treatment and the increased severity of acute oxaliplatin neurotoxicity mostly increase the risk for developing CINP. OXA‐treated patients present less possibilities to recover from CINP after chemotherapy discontinuation, than other chemotherapies.</description><identifier>ISSN: 1085-9489</identifier><identifier>EISSN: 1529-8027</identifier><identifier>DOI: 10.1111/jns.12616</identifier><identifier>PMID: 38311337</identifier><language>eng</language><publisher>Malden, USA: Wiley Periodicals, Inc</publisher><subject>Cancer ; Chemotherapy ; chemotherapy‐induced neuropathic pain ; chemotherapy‐induced peripheral neurotoxicity ; Cisplatin ; Diabetes ; Diabetes mellitus ; Diabetic neuropathy ; incidence ; Neuropathy ; Neurotoxicity ; Oxaliplatin ; Paclitaxel ; Patients ; Peripheral neuropathy ; prediction ; Risk factors ; severity</subject><ispartof>Journal of the peripheral nervous system, 2024-03, Vol.29 (1), p.38-46</ispartof><rights>2024 Peripheral Nerve Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3536-3c4f2045fb3e0a5e8d9a2bfaba9ee29a662fdf4a67c981af7042cdd7ed4ba6d73</citedby><cites>FETCH-LOGICAL-c3536-3c4f2045fb3e0a5e8d9a2bfaba9ee29a662fdf4a67c981af7042cdd7ed4ba6d73</cites><orcidid>0000-0001-6895-5047 ; 0000-0002-3286-778X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjns.12616$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjns.12616$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27933,27934,45583,45584</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38311337$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Argyriou, Andreas A.</creatorcontrib><creatorcontrib>Bruna, Jordi</creatorcontrib><creatorcontrib>Kalofonou, Foteini</creatorcontrib><creatorcontrib>Velasco, Roser</creatorcontrib><creatorcontrib>Litsardopoulos, Pantelis</creatorcontrib><creatorcontrib>Alemany, Montse</creatorcontrib><creatorcontrib>Anastopoulou, Garifallia G.</creatorcontrib><creatorcontrib>Kalofonos, Haralabos P.</creatorcontrib><title>Incidence and risk factors for developing chemotherapy‐induced neuropathic pain in 500 cancer patients: A file‐based observational study</title><title>Journal of the peripheral nervous system</title><addtitle>J Peripher Nerv Syst</addtitle><description>Objective
To define the incidence and risk factors for developing chemotherapy‐induced neuropathic pain (CINP).
Methods
Retrospective, file‐based analysis on cancer patients who received any type of conventional chemotherapy and for whom neurological evaluation was asked to reveal the extent of chemotherapy‐induced peripheral neurotoxicity (CIPN) with or without CINP. CINP was assessed by means of the PI‐NRS and Douleur Neuropathique‐4 questionnaire. The total neuropathy score‐clinical version graded the severity of CIPN.
Results
The medical files of 500 chemotherapy‐treated cancer patients were reviewed. Any grade chronic CIPN was disclosed in 343 (68.6%) patients and CINP in 127 (37%) of them, corresponding to an overall percentage of 25.4% among all 500 included patients. The logistic regression analysis identified as independent predictors for CINP development the presence of uncomplicated diabetes (OR: 2.17; p = .039) and grade 2–3 chronic CIPN (OR: 1.61; p < .001) as also the administration of combined paclitaxel plus cisplatin (reference variable), compared to oxaliplatin (OR: 0.18; p = .001) and taxanes (OR: 0.16; p < .001). The increased severity of acute OXAIPN was associated with CINP (OR: 4.51; p < .001). OXA‐treated patients with persistent CINP presented a worst likelihood to improve after chemotherapy discontinuation, than patients receiving combined paclitaxel plus cisplatin (OR: 50; p < .001).
Conclusion
The incidence of CINP in our cohort was comparable to previous reports, with severities fluctuating upwards during chemotherapy and declined post‐chemotherapy. Uncomplicated diabetes, the combined paclitaxel plus cisplatin treatment and the increased severity of acute oxaliplatin neurotoxicity mostly increase the risk for developing CINP. OXA‐treated patients present less possibilities to recover from CINP after chemotherapy discontinuation, than other chemotherapies.</description><subject>Cancer</subject><subject>Chemotherapy</subject><subject>chemotherapy‐induced neuropathic pain</subject><subject>chemotherapy‐induced peripheral neurotoxicity</subject><subject>Cisplatin</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetic neuropathy</subject><subject>incidence</subject><subject>Neuropathy</subject><subject>Neurotoxicity</subject><subject>Oxaliplatin</subject><subject>Paclitaxel</subject><subject>Patients</subject><subject>Peripheral neuropathy</subject><subject>prediction</subject><subject>Risk factors</subject><subject>severity</subject><issn>1085-9489</issn><issn>1529-8027</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp1kc9uFSEUh4mxsbW68AUMiZu6mJY_M8Pgrmm01jS6UNeTM3Dwcp0LI8zU3J0P4KLP2Ccp9bYuTCQknMB3vgA_Ql5wdszLOFmHfMxFy9tH5IA3QlcdE-pxqVnXVLru9D55mvOaMa4010_Ivuwk51KqA_L7IhhvMRikECxNPn-nDswcU6YuJmrxCsc4-fCNmhVu4rzCBNP25te1D3YxaGnAJcUJ5pU3dAIfaJkNY9RAkaayNXsMc35DT6nzI5bOAXLpi0PGdFVOY4CR5nmx22dkz8GY8fn9eki-vnv75ex9dfnp_OLs9LIyspFtJU3tBKsbN0hk0GBnNYjBwQAaUWhoW-Gsq6FVRnccnGK1MNYqtPUArVXykBztvFOKPxbMc7_x2eA4QsC45F5oUV4gha4L-uofdB2XVG58R0nFhRJtV6jXO8qkmHNC10_JbyBte876u4j6ElH_J6LCvrw3LsMG7V_yIZMCnOyAn-W7tv839R8-ft4pbwGyOJ91</recordid><startdate>202403</startdate><enddate>202403</enddate><creator>Argyriou, Andreas A.</creator><creator>Bruna, Jordi</creator><creator>Kalofonou, Foteini</creator><creator>Velasco, Roser</creator><creator>Litsardopoulos, Pantelis</creator><creator>Alemany, Montse</creator><creator>Anastopoulou, Garifallia G.</creator><creator>Kalofonos, Haralabos P.</creator><general>Wiley Periodicals, Inc</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6895-5047</orcidid><orcidid>https://orcid.org/0000-0002-3286-778X</orcidid></search><sort><creationdate>202403</creationdate><title>Incidence and risk factors for developing chemotherapy‐induced neuropathic pain in 500 cancer patients: A file‐based observational study</title><author>Argyriou, Andreas A. ; Bruna, Jordi ; Kalofonou, Foteini ; Velasco, Roser ; Litsardopoulos, Pantelis ; Alemany, Montse ; Anastopoulou, Garifallia G. ; Kalofonos, Haralabos P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3536-3c4f2045fb3e0a5e8d9a2bfaba9ee29a662fdf4a67c981af7042cdd7ed4ba6d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cancer</topic><topic>Chemotherapy</topic><topic>chemotherapy‐induced neuropathic pain</topic><topic>chemotherapy‐induced peripheral neurotoxicity</topic><topic>Cisplatin</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetic neuropathy</topic><topic>incidence</topic><topic>Neuropathy</topic><topic>Neurotoxicity</topic><topic>Oxaliplatin</topic><topic>Paclitaxel</topic><topic>Patients</topic><topic>Peripheral neuropathy</topic><topic>prediction</topic><topic>Risk factors</topic><topic>severity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Argyriou, Andreas A.</creatorcontrib><creatorcontrib>Bruna, Jordi</creatorcontrib><creatorcontrib>Kalofonou, Foteini</creatorcontrib><creatorcontrib>Velasco, Roser</creatorcontrib><creatorcontrib>Litsardopoulos, Pantelis</creatorcontrib><creatorcontrib>Alemany, Montse</creatorcontrib><creatorcontrib>Anastopoulou, Garifallia G.</creatorcontrib><creatorcontrib>Kalofonos, Haralabos P.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the peripheral nervous system</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Argyriou, Andreas A.</au><au>Bruna, Jordi</au><au>Kalofonou, Foteini</au><au>Velasco, Roser</au><au>Litsardopoulos, Pantelis</au><au>Alemany, Montse</au><au>Anastopoulou, Garifallia G.</au><au>Kalofonos, Haralabos P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence and risk factors for developing chemotherapy‐induced neuropathic pain in 500 cancer patients: A file‐based observational study</atitle><jtitle>Journal of the peripheral nervous system</jtitle><addtitle>J Peripher Nerv Syst</addtitle><date>2024-03</date><risdate>2024</risdate><volume>29</volume><issue>1</issue><spage>38</spage><epage>46</epage><pages>38-46</pages><issn>1085-9489</issn><eissn>1529-8027</eissn><abstract>Objective
To define the incidence and risk factors for developing chemotherapy‐induced neuropathic pain (CINP).
Methods
Retrospective, file‐based analysis on cancer patients who received any type of conventional chemotherapy and for whom neurological evaluation was asked to reveal the extent of chemotherapy‐induced peripheral neurotoxicity (CIPN) with or without CINP. CINP was assessed by means of the PI‐NRS and Douleur Neuropathique‐4 questionnaire. The total neuropathy score‐clinical version graded the severity of CIPN.
Results
The medical files of 500 chemotherapy‐treated cancer patients were reviewed. Any grade chronic CIPN was disclosed in 343 (68.6%) patients and CINP in 127 (37%) of them, corresponding to an overall percentage of 25.4% among all 500 included patients. The logistic regression analysis identified as independent predictors for CINP development the presence of uncomplicated diabetes (OR: 2.17; p = .039) and grade 2–3 chronic CIPN (OR: 1.61; p < .001) as also the administration of combined paclitaxel plus cisplatin (reference variable), compared to oxaliplatin (OR: 0.18; p = .001) and taxanes (OR: 0.16; p < .001). The increased severity of acute OXAIPN was associated with CINP (OR: 4.51; p < .001). OXA‐treated patients with persistent CINP presented a worst likelihood to improve after chemotherapy discontinuation, than patients receiving combined paclitaxel plus cisplatin (OR: 50; p < .001).
Conclusion
The incidence of CINP in our cohort was comparable to previous reports, with severities fluctuating upwards during chemotherapy and declined post‐chemotherapy. Uncomplicated diabetes, the combined paclitaxel plus cisplatin treatment and the increased severity of acute oxaliplatin neurotoxicity mostly increase the risk for developing CINP. OXA‐treated patients present less possibilities to recover from CINP after chemotherapy discontinuation, than other chemotherapies.</abstract><cop>Malden, USA</cop><pub>Wiley Periodicals, Inc</pub><pmid>38311337</pmid><doi>10.1111/jns.12616</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-6895-5047</orcidid><orcidid>https://orcid.org/0000-0002-3286-778X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1085-9489 |
| ispartof | Journal of the peripheral nervous system, 2024-03, Vol.29 (1), p.38-46 |
| issn | 1085-9489 1529-8027 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2925003294 |
| source | Access via Wiley Online Library |
| subjects | Cancer Chemotherapy chemotherapy‐induced neuropathic pain chemotherapy‐induced peripheral neurotoxicity Cisplatin Diabetes Diabetes mellitus Diabetic neuropathy incidence Neuropathy Neurotoxicity Oxaliplatin Paclitaxel Patients Peripheral neuropathy prediction Risk factors severity |
| title | Incidence and risk factors for developing chemotherapy‐induced neuropathic pain in 500 cancer patients: A file‐based observational study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-30T07%3A28%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20and%20risk%20factors%20for%20developing%20chemotherapy%E2%80%90induced%20neuropathic%20pain%20in%20500%20cancer%20patients:%20A%20file%E2%80%90based%20observational%20study&rft.jtitle=Journal%20of%20the%20peripheral%20nervous%20system&rft.au=Argyriou,%20Andreas%20A.&rft.date=2024-03&rft.volume=29&rft.issue=1&rft.spage=38&rft.epage=46&rft.pages=38-46&rft.issn=1085-9489&rft.eissn=1529-8027&rft_id=info:doi/10.1111/jns.12616&rft_dat=%3Cproquest_cross%3E2937127268%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2937127268&rft_id=info:pmid/38311337&rfr_iscdi=true |